First AI-designed drug hits Phase 3; Insilico releases 4B kinase specialist model
CatAstro_Piyush · x · 2026-09-10
Insilico Medicine announced that Rentosertib, the first AI-designed drug, has entered Phase 3 trials. It inhibits TNIK, a kinase that acts as a molecular switch inside cells.
The core challenge with kinases is selectivity: their binding pockets are remarkably similar, so a molecule designed for one may hit others. To address this, the company also released InsilicoMMAI-4B-Chem-Kinome, a 4B-parameter specialist language model claiming SOTA+ performance across 31 kinase targets.
More from AGI Musings
- CS professor: don't hide your AI use from future employers, lead with it — lemire · 2026-10-26
- Engineer: AI-cheap engineering will change which manufacturing jobs get a yes — burhop · 2026-10-26
- FixItBench: the joke benchmark where robot-agent teams race to repair electron microscopes — teortaxesTex · 2026-10-26
- Instructor advice: record and save all your teaching materials for future AI use — prof_g · 2026-10-26
- Jason Furman: Building Econvitals pre-AI would need ~50 people, 3 years, $20M — HarrySurden · 2026-10-26
- Dune's 1960s Warning on Handing Thinking to Machines Resurfaces in AI Debate — umeshonai · 2026-10-26